University Medical Center Groningen
Groningen, 9700 RB, Netherlands
NCT Number: NCT03578510
Intradialytic hypotension (IDH) is a frequent and serious complication that may occur during hemodialysis treatment. The investigators and others have shown that the Hemocontrol biofeedback system is associated with improved hemodynamic stability. Hemocontrol is a technique that guides the patients' blood volume along a pre-set trajectory by continuously adjusting the ultrafiltration rate and dialysate conductivity. In a recent pilotstudy, the investigators found significantly higher plasma vasopressin levels during the first hour of dialysis with Hemocontrol in comparison with standard hemodialysis. Increased vasopressin levels may contribute to intradialytic hemodynamic stability during hemodialysis by enhanced vasoconstriction. These results, however, did not prove directly that the improved hemodynamic stability with Hemocontrol is indeed caused by higher initial plasma vasopressin levels. Alternative explanations might be that 1) the higher initial plasma sodium levels with Hemocontrol dialysis enhance activity of the sympathetic nervous system directly, causing vasoconstriction and thereby improved hemodynamic stability and/or 2) that the higher initial plasma levels of sodium in Hemocontrol inhibit the release of nitric oxide by the vascular endothelium. Another goal of this study is to investigate whether vasopressin is removed with hemodialysis.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Groningen, 9700 RB, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis blood is withdrawn from the dialysis line to determine plasma levels of vasopressin.
Plasma levels of the antidiuretic hormone, i.e. vasopressin
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
Time frame: Before, after 30, 60, 120 and 180 minutes and after dialysis
University Medical Center Groningen
Other
Is the Lower Incidence of Intradialytic Hypotension During Hemocontrol Dialysis in Comparison With Standard Hemodialysis Attributable to Enhanced to Higher Plasma Vasopressin Levels or to Enhanced Sympathetic Activity and/or to Less Nitric Oxide Production
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00072683
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial DetailsNCT00201994
Brain Diseases, Cardiovascular Diseases
Gustav Carus, Dresden, Germany
View Trial DetailsNCT06155812
Diabetes Insipidus, Endocrine System Diseases
Zagreb, Croatia
View Trial DetailsNCT05190744
Abnormalities, Multiple, Acquired Nephrogenic Diabetes Insipidus
Jacksonville, Florida, United States
View Trial Details